Multiple Trial And Dilution Risks Will Shape Future Immunology Upside Potential

Catalysts

About Corvus Pharmaceuticals

Corvus Pharmaceuticals focuses on developing soquelitinib, a selective ITK inhibitor, for immune mediated diseases and cancers.

What are the underlying business or industry changes driving this perspective?

• Although soquelitinib spans atopic dermatitis, peripheral T cell lymphoma, hidradenitis suppurativa, asthma and ALPS, the company faces execution risk in running multiple global trials through at least 2027. This could pressure R&D spending and delay any future revenue recognition.
• Although the oral atopic dermatitis profile includes 72% mean EASI reduction in cohort 4 and 75% of patients reaching EASI 75 at 8 weeks, the Phase II trial is blinded and runs to mid 2027. Any setback in efficacy or durability could limit pricing power and keep future earnings under pressure.
• Although the large asthma and hidradenitis suppurativa markets are already familiar with IL 17 and other targeted therapies, soquelitinib still needs to show clear benefit across both Th2 and Th17 driven disease. If results are mixed, that could cap long term revenue potential and constrain margin expansion.
• Although the Phase III PTCL trial uses an oral regimen against chemotherapy comparators with short historical PFS and OS figures, the open label design and reliance on an interim futility analysis mean any weaker than expected survival data could limit future oncology sales and leave fixed development costs weighing on net margins.
• Although Corvus holds approximately US$246m of pro forma cash with runway into Q2 2028, the higher 2025 R&D expenses of US$33.7m and a net loss of US$12.3m in Q4 2025 indicate that any extension of timelines or new indications could require additional funding. This may dilute shareholders and impact per share earnings power.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on Corvus Pharmaceuticals compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• Corvus Pharmaceuticals currently has no revenue. The bearish analysts are forecasting revenue to reach $11.7 million by April 2029.
• The bearish analysts are not forecasting that Corvus Pharmaceuticals will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Corvus Pharmaceuticals's profit margin will increase from 0.0% to the average US Biotechs industry of 14.8% in 3 years.
• If Corvus Pharmaceuticals's profit margin were to converge on the industry average, you could expect earnings to reach $1.7 million (and earnings per share of $0.02) by about April 2029, up from -$15.3 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $5.9 million in earnings, and the most bearish expecting $-141.2 million.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 1979.5x on those 2029 earnings, up from -80.7x today. This future PE is greater than the current PE for the US Biotechs industry at 14.9x.
• The bearish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.07%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Corvus is still a clinical stage company with no revenue today and bearish analysts only model US$11.7 million of revenue by April 2029. Any delay, failure or redesign in its multiple trials for atopic dermatitis, PTCL, hidradenitis suppurativa, asthma or ALPS could leave the company without a clear path to commercial sales, putting long term revenue at risk.
• Research and development expenses were US$33.7 million in 2025 compared with US$19.4 million in 2024 and the company reported a net loss of US$12.3 million in Q4 2025. If the broader biotech sector continues to require high R&D intensity and longer development cycles, sustained spending without offsetting income could keep earnings and net margins under pressure even if cash runway currently extends into Q2 2028.
• The valuation framework described by bearish analysts requires Corvus to trade at a P/E of 1,979.5x on estimated 2029 earnings of US$1.7 million compared with a current industry P/E of 14.9x. If market sentiment toward high multiple, loss making biotech names moderates over time, the share price may not support such a multiple, which would directly affect future earnings based valuation and expectations for earnings per share.
• Analysts expect shares outstanding to grow by 7.0% per year for the next 3 years and management has already raised about US$200 million in equity financing. If capital markets for biotech remain more reliant on equity than non dilutive funding, repeated capital raises could dilute existing holders and offset any future growth in earnings per share or per share cash flows.
• Analyst forecasts show wide disagreement, from US$5.9 million of earnings at the bullish end to a loss of US$141.2 million at the bearish end by around 2029. If long term biotech sector trends such as higher trial complexity and tighter payer scrutiny persist, Corvus could track closer to the bearish case, which would materially affect both net margins and the likelihood of achieving the assumed 14.8% profit margin used in the scenario.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Corvus Pharmaceuticals is $27.0, which represents up to two standard deviations below the consensus price target of $35.17. This valuation is based on what can be assumed as the expectations of Corvus Pharmaceuticals's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $51.0, and the most bearish reporting a price target of just $27.0.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $11.7 million, earnings will come to $1.7 million, and it would be trading on a PE ratio of 1979.5x, assuming you use a discount rate of 7.1%.
• Given the current share price of $14.69, the analyst price target of $27.0 is 45.6% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.